المؤلفون: Zeverijn LJ; Netherlands Cancer Institute, Amsterdam, Netherlands., Geurts BS; Netherlands Cancer Institute, Netherlands., Battaglia TW; Netherlands Cancer Institute, Amsterdam, Netherlands., van Berge Henegouwen JM; Erasmus MC, Rotterdam, Netherlands., de Wit GF; Netherlands Cancer Institute, Amsterdam, Netherlands., Hoes LR; Netherlands Cancer Institute, Amsterdam, Netherlands., van der Wijngaart H; Maastricht University Medical Centre, Netherlands., van der Noort V; Netherlands Cancer Institute, Amsterdam, Netherlands., Roepman P; Hartwig Medical Foundation, Amsterdam, Netherlands., de Leng WWJ; University Medical Center Utrecht, Utrecht, Utrecht, Netherlands., Jansen AML; University Medical Center Utrecht, Utrecht, Utrecht, Netherlands., Chalabi M; Netherlands Cancer Institute, Amsterdam, Netherlands., van Herpen CML; Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands., Devriese LA; University Medical Center Utrecht Cancer Center, Utrecht, Netherlands., Erdkamp FLG; Zuyderland Medisch Centrum, Netherlands., Labots M; Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, Netherlands., de Jonge MJA; Erasmus MC Cancer Institute, Rotterdam, Netherlands., Kerver ED; Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands., Bins AD; Amsterdam UMC, Amsterdam, Netherlands., Leek LVM; Netherlands Cancer Institute, Amsterdam, Netherlands., Notohardjo JCL; Amsterdam UMC Location VUmc, Amsterdam, Netherlands., van den Eertwegh AJM; Amsterdam UMC, Netherlands., Wessels LFA; The Netherlands Cancer Institute, Amsterdam, NH, Netherlands., Verheul HMW; Erasmus MC, Rotterdam, Netherlands., Gelderblom H; Leiden University Medical Center, Leiden, Netherlands., van de Haar J; The Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands., Voest EE; Netherlands Cancer Institute, Amsterdam, Netherlands.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Jul 18. Date of Electronic Publication: 2024 Jul 18.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

المؤلفون: Geurts BS; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Zeverijn LJ; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., van Berge Henegouwen JM; Department of Clinical Genetics, Erasmus Medical Center, Leiden, The Netherlands., van der Wijngaart H; Department of Medical Oncology, GROW, Maastricht University Medical Center, Maastricht, The Netherlands., Hoes LR; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., de Wit GF; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Spiekman IA; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands., Battaglia TW; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., van Beek DM; Hartwig Medical Foundation, Amsterdam, The Netherlands., Roepman P; Hartwig Medical Foundation, Amsterdam, The Netherlands., Jansen AM; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., de Leng WW; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., Broeks A; Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands., Labots M; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands., van Herpen CM; Department of Medical Oncology, Radboud Medical Center, Nijmegen, The Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Verheul HM; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands., Snaebjornsson P; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Faculty of Medicine, University of Iceland, Reykjavik, Iceland., Voest EE; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.

المصدر: The Journal of pathology [J Pathol] 2024 Jul; Vol. 263 (3), pp. 288-299. Date of Electronic Publication: 2024 May 15.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: John Wiley And Sons Country of Publication: England NLM ID: 0204634 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-9896 (Electronic) Linking ISSN: 00223417 NLM ISO Abbreviation: J Pathol Subsets: MEDLINE

مواضيع طبية MeSH: Microsatellite Instability* , DNA Mismatch Repair* , Immune Checkpoint Inhibitors*/therapeutic use, Humans ; Female ; Male ; Middle Aged ; Aged ; Immunotherapy/methods ; Whole Genome Sequencing ; Adult ; Biomarkers, Tumor/genetics ; Neoplasms/genetics ; Neoplasms/therapy ; Neoplasms/pathology ; Aged, 80 and over ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/pathology ; Colorectal Neoplasms/therapy

المؤلفون: van Berge Henegouwen JM; Erasmus MC, Rotterdam, Netherlands., Zeverijn LJ; Netherlands Cancer Institute, Amsterdam, Netherlands., Geurts BS; Netherlands Cancer Institute, Netherlands., Hoes LR; Netherlands Cancer Institute, Amsterdam, Netherlands., van der Wijngaart H; Maastricht University Medical Centre, Netherlands., van der Noort V; Netherlands Cancer Institute, Amsterdam, Netherlands., Huitema ADR; Netherlands Cancer Institute, Amsterdam, Netherlands., De Vos FYF; University Medical Center Utrecht, Utrecht, Netherlands., Grünberg K; Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands., Bloemendal HJ; Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands., Verheul HMW; Erasmus MC, Rotterdam, Netherlands., Voest EE; Netherlands Cancer Institute, Amsterdam, Netherlands., Gelderblom H; Leiden University Medical Center, Leiden, Netherlands.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Jun 27. Date of Electronic Publication: 2024 Jun 27.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

المؤلفون: Haj Mohammad SF; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands. s.f.haj_mohammad@lumc.nl., Timmer HJL; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Zeverijn LJ; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Geurts BS; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Spiekman IAC; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Verkerk K; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Verbeek FAJ; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Verheul HMW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Voest EE; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.

المصدر: Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2024 May 23; Vol. 63, pp. 368-372. Date of Electronic Publication: 2024 May 23.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Medical Journals Sweden AB Country of Publication: Sweden NLM ID: 8709065 Publication Model: Electronic Cited Medium: Internet ISSN: 1651-226X (Electronic) Linking ISSN: 0284186X NLM ISO Abbreviation: Acta Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Neoplasms*/drug therapy , Neoplasms*/genetics , Precision Medicine*/methods, Humans ; Netherlands ; Immunotherapy/methods ; Medical Oncology/methods ; Medical Oncology/trends ; Piperazines/therapeutic use ; Pyridines/therapeutic use ; Nivolumab/therapeutic use ; Antineoplastic Agents/therapeutic use ; Molecular Targeted Therapy/methods

المؤلفون: Spiekman IAC; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands., Geurts BS; Oncode Institute, Utrecht, The Netherlands.; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Zeverijn LJ; Oncode Institute, Utrecht, The Netherlands.; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., de Wit GF; Oncode Institute, Utrecht, The Netherlands.; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Noort V; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Roepman P; Hartwig Medical Foundation, Amsterdam, The Netherlands., de Leng WWJ; Department of Pathology, University Medical Cancer Center Utrecht, Utrecht, The Netherlands., Jansen AML; Department of Pathology, University Medical Cancer Center Utrecht, Utrecht, The Netherlands., Kusters B; Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands., Beerepoot LV; Department of Internal Medicine, ETZ Hospital (Elisabeth-TweeSteden Ziekenhuis), Tilburg, The Netherlands., de Vos FYFL; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., de Groot DA; Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands., de Groot JWB; Isala Oncology Center, Isala, Zwolle, The Netherlands., Hoeben A; Division of Medical Oncology, Department of Internal Medicine, GROW School of Oncology and Development Biology, Maastricht University Center+, Maastricht, The Netherlands., Buter J; Department of Medical Oncology, Amsterdam University Medical Center, Location VuMC, Amsterdam, The Netherlands., Gelderblom HAJ; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Voest EE; Oncode Institute, Utrecht, The Netherlands.; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Center for Personalized Cancer Treatment, Rotterdam,The Netherlands., Verheul HMW; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands.

المصدر: The oncologist [Oncologist] 2024 May 03; Vol. 29 (5), pp. 431-440.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

مواضيع طبية MeSH: Panitumumab*/therapeutic use , Panitumumab*/adverse effects , Panitumumab*/pharmacology , Glioblastoma*/drug therapy , Glioblastoma*/genetics , Glioblastoma*/pathology , Glioblastoma*/mortality, Humans ; Female ; Male ; Middle Aged ; Aged ; Adult ; Brain Neoplasms/drug therapy ; Brain Neoplasms/genetics ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Agents, Immunological/adverse effects ; ras Proteins/genetics ; raf Kinases/genetics ; raf Kinases/antagonists & inhibitors

المؤلفون: Spiekman IAC; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands., Zeverijn LJ; Oncode Institute, Utrecht, the Netherlands; Department of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Geurts BS; Oncode Institute, Utrecht, the Netherlands; Department of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Verkerk K; Oncode Institute, Utrecht, the Netherlands; Department of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Haj Mohammad SF; Department of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., van der Noort V; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands., Roepman P; Hartwig Medical Foundation, Amsterdam, the Netherlands., de Leng WWJ; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., Jansen AML; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., Gootjes EC; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., de Groot DA; Department of Medical Oncology, University Medical Center Groningen, Groningen, the Netherlands., Kerver ED; Department of Medical Oncology, OLVG, Amsterdam, the Netherlands., van Voorthuizen T; Department of Medical Oncology, Rijnstate, Arnhem, the Netherlands., Roodhart JML; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands., Valkenburg-van Iersel LBJ; Division of Medical Oncology, Department of Internal Medicine, GROW school of Oncology and Development Biology, Maastricht University Center+, Maastricht, the Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., Voest EE; Oncode Institute, Utrecht, the Netherlands; Department of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Verheul HMW; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands. Electronic address: h.verheul@erasmusmc.nl.

المصدر: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 May; Vol. 202, pp. 113988. Date of Electronic Publication: 2024 Mar 07.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized* , Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/genetics , Receptor, ErbB-2*/genetics, Humans ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Proto-Oncogene Proteins B-raf/genetics ; Trastuzumab/adverse effects ; Trastuzumab/therapeutic use

المؤلفون: Battaglia TW; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Division of Molecular Carcinogenesis, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Mimpen IL; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Traets JJH; Division of Tumor Biology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., van Hoeck A; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Department of Head and Neck Surgery and Oncology, the Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands., Zeverijn LJ; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Geurts BS; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., de Wit GF; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Noë M; Department of Pathology, Antoni van Leeuwenhoek/the Netherlands Cancer Institute, Amsterdam, the Netherlands., Hofland I; Core Facility Molecular Pathology & Biobanking, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Vos JL; Division of Tumor Biology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Head and Neck Service and Immunogenomic Oncology Platform, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Cornelissen S; Core Facility Molecular Pathology & Biobanking, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Alkemade M; Core Facility Molecular Pathology & Biobanking, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Broeks A; Core Facility Molecular Pathology & Biobanking, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Zuur CL; Division of Tumor Biology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Department of Head and Neck Surgery and Oncology, the Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Department of Otorhinolaryngology Head and Neck Surgery, Leiden University Medical Center, Leiden, the Netherlands., Cuppen E; Center for Molecular Medicine, University Medical Centre Utrecht, Utrecht 3584CX, the Netherlands; Hartwig Medical Foundation, Science Park, Amsterdam 1098XH, the Netherlands., Wessels L; Division of Molecular Carcinogenesis, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Faculty of EEMCS, Delft University of Technology, Delft 2628 CD, the Netherlands., van de Haar J; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Voest E; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands. Electronic address: e.voest@nki.nl.

المصدر: Cell [Cell] 2024 Apr 25; Vol. 187 (9), pp. 2324-2335.e19. Date of Electronic Publication: 2024 Apr 09.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 0413066 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-4172 (Electronic) Linking ISSN: 00928674 NLM ISO Abbreviation: Cell Subsets: MEDLINE

مواضيع طبية MeSH: Microbiota* , Neoplasm Metastasis* , Neoplasms*/microbiology , Neoplasms*/pathology, Humans ; Metagenomics/methods ; Lung Neoplasms/microbiology ; Lung Neoplasms/pathology ; Immune Checkpoint Inhibitors/therapeutic use ; Immune Checkpoint Inhibitors/pharmacology ; Neutrophils/immunology ; Tumor Microenvironment ; Bacteria/genetics ; Bacteria/classification

المؤلفون: Geurts BS; Netherlands Cancer Institute, Netherlands., Zeverijn LJ; Netherlands Cancer Institute, Amsterdam, Netherlands., Leek LVM; Netherlands Cancer Institute, Amsterdam, Netherlands., van Berge Henegouwen JM; Erasmus MC, Rotterdam, Netherlands., Hoes LR; Netherlands Cancer Institute, Amsterdam, Netherlands., van der Wijngaart H; Maastricht University Medical Centre, Netherlands., van der Noort V; Netherlands Cancer Institute, Amsterdam, Netherlands., van de Haar J; The Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands., van Ommen-Nijhof A; The Netherlands Cancer Institute, Netherlands., Kok M; Netherlands Cancer Institute, Amsterdam, Netherlands., Roepman P; Hartwig Medical Foundation, Amsterdam, Netherlands., Jansen AML; University Medical Center Utrecht, Utrecht, Utrecht, Netherlands., de Leng WWJ; University Medical Center Utrecht, Utrecht, Utrecht, Netherlands., de Jonge MJA; Erasmus MC Cancer Institute, Rotterdam, Netherlands., Hoeben A; Maastricht University Medical Centre, Maastricht, Netherlands., van Herpen CML; Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands., Westgeest HM; Amphia Ziekenhuis, Breda, Netherlands., Wessels LFA; The Netherlands Cancer Institute, Amsterdam, NH, Netherlands., Verheul HMW; Erasmus MC, Rotterdam, Netherlands., Gelderblom H; Leiden University Medical Center, Leiden, Netherlands., Voest EE; Netherlands Cancer Institute, Amsterdam, Netherlands.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Apr 17. Date of Electronic Publication: 2024 Apr 17.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

المؤلفون: Verkerk K; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Geurts BS; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Zeverijn LJ; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., van der Noort V; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands., Verheul HMW; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands., Haanen JBAG; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Clinical Oncology, LUMC, Leiden, the Netherlands.; Head of Melanoma Clinic, CHUV, Lausanne, Switzerland., van der Veldt AAM; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands.; Department of Radiology & Nuclear Medicine, Erasmus Medical Center, Rotterdam, the Netherlands., Eskens FALM; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands., Aarts MJB; Department of Medical Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands., van Herpen CML; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Jalving M; Department of Medical Oncology, University of Medical Center Groningen, Groningen, the Netherlands., Gietema JA; Department of Medical Oncology, University of Medical Center Groningen, Groningen, the Netherlands., Devriese LA; Department of Medical Oncology, Division Beeld & Oncologie, Utrecht University Medical Center, Utrecht, the Netherlands., Labots M; Department of Medical Oncology, Amsterdam University Medical Center, Location VUMC, Cancer Center Amsterdam, the Netherlands., Barjesteh van Waalwijk van Doorn-Khosrovani S; CZ Health Insurance, Tilburg, the Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., Smit EF; Department of Pulmonology, Leiden University Medical Center, Leiden, the Netherlands., Bloemendal HJ; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.

المصدر: The Lancet regional health. Europe [Lancet Reg Health Eur] 2024 Mar 05; Vol. 39, pp. 100875. Date of Electronic Publication: 2024 Mar 05 (Print Publication: 2024).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: [Oxford] Country of Publication: England NLM ID: 101777707 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-7762 (Electronic) Linking ISSN: 26667762 NLM ISO Abbreviation: Lancet Reg Health Eur Subsets: PubMed not MEDLINE

المؤلفون: Zeverijn LJ; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Looze EJ; Division of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Thavaneswaran S; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., van Berge Henegouwen JM; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Simes RJ; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., Hoes LR; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Sjoquist KM; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., van der Wijngaart H; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands., Sebastian L; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., Geurts BS; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Lee CK; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., de Wit GF; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Espinoza D; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., Roepman P; Hartwig Medical Foundation, Amsterdam, The Netherlands., Lin FP; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., Jansen AML; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., de Leng WWJ; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., van der Noort V; Biometrics Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Leek LVM; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands., de Vos FYFL; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., van Herpen CML; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Verheul HMW; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands., Thomas DM; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia., Voest EE; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.

المصدر: International journal of cancer [Int J Cancer] 2023 Oct 01; Vol. 153 (7), pp. 1413-1422. Date of Electronic Publication: 2023 Jul 10.

نوع المنشور: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0215 (Electronic) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Neoplasms*/drug therapy , Breast Neoplasms*/drug therapy, Humans ; Female ; Cyclins ; Australia ; Precision Medicine ; Aminopyridines/therapeutic use ; Cyclin D ; Cyclin-Dependent Kinase 4 ; Protein Kinase Inhibitors/pharmacology ; Cyclin-Dependent Kinase 6 ; DNA Helicases ; Nuclear Proteins